Hungary’s Egis Pharmaceuticals has bolstered its OTC portfolio in its domestic market with the acquisition of skin-care brand Neogranormon from Teva Pharmaceutical Industries for an undisclosed sum.
Hungary’s Egis Picks Up Skin-Care Portfolio From Teva
Egis is the beneficiary as Teva again trims its OTC portfolio with the sale of Hungarian skin-care brand Neogranormon.
More from Deals
More from Strategy
• By
New Estee Lauder President and CEO Stéphane de La Faverie unveils "Beauty Reimagined" restructuring effort to expand its recovery plan and unleash innovation to restore sustainable sales growth over next few years. The largest operational transformation in its history will include cutting up to 7,000 jobs and total charges of $1.2bn-$1.6bn, while grossing annual savings of $800m-$1bn.
• By
Egis is the beneficiary as Teva again trims its OTC portfolio with the sale of Hungarian skin-care brand Neogranormon.
• By
Kenvue's EMEA and LATAM head Carlton Lawson acknowledges the urgency of environmental issues like antimicrobial resistance and wastewater pollution in this interview with HBW Insight, but calls for a more balanced approach on the part of European regulators.